Alucent Biomedical, Inc. is a privately held company pioneering a new approach for improving the success rate of arteriovenous fistula (AVF) maturation. Using the Alucent Natural Vascular Scaffolding , the company aims to improve vascular access for the millions of patients requiring life-saving kidney replacement therapy through hemodialysis. Alucent Biomedical was founded in 2017 by the Avera Research Institute, part of the multistate Avera Health system.
©
Leadership
Scientific Advisory Board
Scott Berceli, MD, PhD
Professor of Surgery and Vice-Chair of Research for the Department of Surgery, University of Florida
Venita Chandra, MD, FACS
Clinical Professor of Surgery in the Division of Vascular Surgery, Stanford University
Laura Dember, MD
Professor of Medicine (Renal-Electrolyte and Hypertension) at the Hospital of the University of Pennsylvania
Ellen Dillavou, MD, FACS, RPVI
Division Chief of Vascular Surgery, WakeMed Hospitals
Bart Dolmatch, MD
Interventional Radiologist, The Palo Alto Medical Foundation
Larry Kraiss, MD
Professor and Chief of the Division of Vascular Surgery, University of Utah
William Sessa, PhD
Professor and Vice Chairman in the Department of Pharmacology and Director of the Vascular Biology & Therapeutics Program, Yale School of Medicine
Board of Directors
James Corbett
Chairman of the Board
Chief Executive Officer, AVITA Medical
David Flicek
Director
Chief Operating Officer, Avera Health
Myles Greenberg, MD
Director
Chief Executive Officer, Alucent Biomedical
Julie Lautt
Director
Chief Financial Officer, Avera Health
Dan Pelak
Retired CEO Closure Medical Corp., and Retired Operating Partner Welsh Carson Anderson and Stowe
Andreas Wuepper, PhD
Observer
Managing Director, Fresenius Medical Care Ventures